New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

Orlando, Fla., Florida United States of America
40-50% of patients no longer needed CPAP devices after taking tirzepatide
Lowered C-reactive protein levels and systolic blood pressure
Patients lost an average of 18% to 20% of their body weight during the trial period
Tirzepatide injection shows promise in treating obstructive sleep apnea (OSA)
New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

In a major breakthrough for the treatment of obstructive sleep apnea (OSA), Eli Lilly and Company has announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection. The drug, which is currently an effective diabetes and weight loss solution under the names Mounjaro for type 2 diabetes and Zepbound for obesity, showed significant potential in reducing sleep disruptions in patients with obesity and OSA. According to the trials, 40% to 50% of patients no longer needed a continuous positive airway pressure (CPAP) device after taking tirzepatide. In addition to its impact on sleep apnea, tirzepatide also lowered C-reactive protein levels and systolic blood pressure while patients lost an average of 18% to 20% of their body weight during the trial period. The SURMOUNT-OSA studies mark a significant milestone in the treatment of OSA, offering a promising new therapeutic option for those suffering from this widespread condition.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

100%

No Doubts Found At Time Of Publication

Sources

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Experts split on whether Eli Lilly’s Zepbound will hamper CPAP sales

STAT News Lizzy Lawrence, Tuesday, 25 June 2024 08:30
  • Unique Points
    • Eli Lilly reported full results of its obesity drug, Zepbound, in sleep apnea patients last week.
    • Zepbound reduced the number of sleep apnea episodes in patients both using and not using CPAP machines according to a trial run by Malhotra.
    • Industry analysts and clinical experts are split on whether Zepbound results indicate another example of ‘Ozempic panic’ or a legitimate warning for CPAP’s decline.
  • Accuracy
    • Shares of leading CPAP maker ResMed dropped 11% and shares of nerve stimulator Inspire sank 17% after data release on late Friday.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution

Eli Lilly and Company Tuesday, 25 June 2024 18:57
  • Unique Points
    • Tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% in the primary endpoint.
    • 43.0% and 51.5% of participants taking tirzepatide at the highest dose reached the criteria for disease resolution as defined by apnea-hypopnea index and Epworth Sleepiness Scale measures.
    • Lilly submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the FDA, will initiate submissions for other global regulatory agencies soon.
    • Mean reduction of up to 62.8% on the apnea-hypopnea index (AHI) compared to placebo, which is about 30 fewer events restricting or blocking a person’s airflow per hour of sleep.
    • OSA can impact the progression of serious cardiometabolic complications including hypertension, coronary heart disease, stroke, heart failure, atrial fibrillation and type 2 diabetes.
  • Accuracy
    • In key secondary endpoints, 43.0% and 51.5% of participants treated with tirzepatide at the highest dose met the criteria for disease resolution.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Why a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling

Investopedia Tuesday, 25 June 2024 18:57
  • Unique Points
    • Eli Lilly released clinical trial data on Friday showing that its weight-loss drug Zepbound can reduce the severity of sleep apnea among obese patients without the use of a traditional sleep apnea mask.
    • Eli Lilly submitted Zepbound to the FDA to get sleep apnea added as a condition it can treat, expecting regulatory action by the end of 2024.
  • Accuracy
    • Zepbound reduced the number of sleep apnea episodes in patients both using and not using CPAP machines according to a trial run by Malhotra.
    • Tirzepatide may be the first drug approved for OSA if it gains FDA approval.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Tirzepatide Significantly Reduces Sleep Disruptions

Medscape Alicia Ault Tuesday, 25 June 2024 18:58
  • Unique Points
    • Tirzepatide is an effective diabetes and weight loss drug.
    • Tirzepatide reduces sleep disruptions in patients with obesity and obstructive sleep apnea (OSA).
    • 40% to 50% of patients no longer needed CPAP device after taking tirzepatide.
    • Tirzepatide lowers C-reactive protein levels and systolic blood pressure.
    • Patients lost 18% to 20% of their body weight while taking tirzepatide.
    • OSA affects over 1 billion people worldwide and 30 million American adults, many of whom are undiagnosed.
  • Accuracy
    • Tirzepatide reduces sleep disruptions in patients with obesity and obstructive sleep apnea (OSA).
    • 40% to 50% of patients no longer needed CPAP device after taking tirzepatide.
    • Zepbound reduced the number of sleep apnea episodes in patients both using and not using CPAP machines according to a trial.
    • Tirzepatide may be the first drug approved for OSA if it gains FDA approval.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication